RxDoctor Payments Data

Consuelo Bartyzal

Family · Medford, ORNPI 1336781863

Payments from drug & device makers

$1,072in general payments, 2019–2025

Across 14 payments — averaging $76.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$236
  • Lilly USA, LLC$185
  • Novo Nordisk$158
  • Otsuka America Pharmaceutical, Inc.$125
  • Axsome Therapeutics, Inc.$119
  • Johnson & Johnson$104
  • plus $146 from 2 others

What the payments were for

  • Food & beverage$1,072100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,072 in reported general payments places this provider in the 85th percentile of 1,130 family providers in Oregon.

See all family providers in Oregon

Medicare billing

Part B allowed, 2024
$53,711
Medicare patients
199
Services billed
940

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide100$102,774
EliquisApixaban71$56,560
XareltoRivaroxaban14$21,151
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$18,352
TrintellixVortioxetine Hydrobromide26$17,187
JardianceEmpagliflozin23$14,676
LinzessLinaclotide16$10,548
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl91$8,350
Spiriva RespimatTiotropium Bromide11$7,044
Aripiprazole39$6,960
MovantikNaloxegol Oxalate12$4,776
VascepaIcosapent Ethyl16$4,662
Fluticasone-SalmeterolFluticasone Propion/Salmeterol48$4,488
Sucralfate28$4,431
Desvenlafaxine Succinate ErDesvenlafaxine Succinate57$3,473

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$158$102,774100 claims
Johnson & JohnsonXarelto$104$21,15114 claims
AstraZenecaSymbicort$236$3,43412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,130 family providers in Oregon.

Other family in Medford

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →